Progress in Procalcitonin Detection Based on Immunoassay  

作　　者：Jiayue Huang Yan Zu Lexiang Zhang Wenguo Cui 

机构地区：[1]State Key Laboratory of Targeting Oncology,National Center for International Research of Bio-targeting Theranostics,Guangxi Key Laboratory of Bio-targeting Theranostics,Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy,Guangxi Medical University,Nanning,Guangxi 530021,P.R.China [2]Oujiang Laboratory(Zhejiang Lab for Regenerative Medicine,Vision and Brain Health),Wenzhou Institute,University of Chinese Academy of Sciences,Wenzhou,Zhejiang 325000,P.R.China [3]Joint Centre of Translational Medicine,the First Affiliated Hospital of Wenzhou Medical University,Wenzhou 325035,P.R.China [4]Department of Orthopedics,Shanghai Key Laboratory for Prevention and Treatment of Bone and Joint Diseases,Shanghai Institute of Traumatology and Orthopedics,Ruijin Hospital,Shanghai Jiao Tong University School of Medicine,197 Ruijin 2nd Road,Shanghai 200025,P.R.China

出　　处：《Research》2024年第4期662-684,共23页研究(英文)

基　　金：supported by the National Natural Science Foundation of China(22307098);the Zhejiang Provincial Natural Science Foundation of China(LGF22C100003);the Wenzhou high-level innovation team(Development and application team of functional liver cancer-on-a-chip);the Wenzhou Basic Research Projects(Y2023147);the Key Projects of Wenzhou Science and Technology Bureau(ZG2023013);the program of WIUCASQD2021012 from Wenzhou Institute,University of Chinese Academy of Sciences;the Scientific and Technological Innovation Major Base of Guangxi(No.2022-36-Z05).

摘　　要：Procalcitonin(PCT)serves as a crucial biomarker utilized in diverse clinical contexts,including sepsis diagnosis and emergency departments.Its applications extend to identifying pathogens,assessing infection severity,guiding drug administration,and implementing theranostic strategies.However,current clinical deployed methods cannot meet the needs for accurate or real-time quantitative monitoring of PCT.This review aims to introduce these emerging PCT immunoassay technologies,focusing on analyzing their advantages in improving detection performances,such as easy operation and high precision.The fundamental principles and characteristics of state-of-the-art methods are first introduced,including chemiluminescence,immunofluorescence,latex-enhanced turbidity,enzyme-linked immunosorbent,colloidal gold immunochromatography,and radioimmunoassay.Then,improved methods using new materials and new technologies are briefly described,for instance,the combination with responsive nanomaterials,Raman spectroscopy,and digital microfluidics.Finally,the detection performance parameters of these methods and the clinical importance of PCT detection are also discussed.

关 键 词：DIAGNOSIS utilized instance 

分 类 号：R73[医药卫生—肿瘤]